arbekacin has been researched along with Critical Illness in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aibiki, M; Fukuoka, N | 1 |
| Ikawa, K; Ikeda, K; Morikawa, N; Suyama, H; Yamanoue, T | 1 |
1 trial(s) available for arbekacin and Critical Illness
| Article | Year |
|---|---|
Recommended dose of arbekacin, an aminoglycoside against methicillin-resistant Staphylococcus aureus, does not achieve desired serum concentration in critically ill patients with lowered creatinine clearance.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bayes Theorem; Creatinine; Critical Illness; Data Interpretation, Statistical; Dibekacin; Dose-Response Relationship, Drug; Female; Fluorescence Polarization Immunoassay; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Staphylococcal Infections; Tissue Distribution | 2008 |
1 other study(ies) available for arbekacin and Critical Illness
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of once-daily arbekacin during continuous venovenous hemodiafiltration in critically ill patients.
Topics: Aged; Anti-Infective Agents; Computer Simulation; Critical Illness; Dibekacin; Drug Administration Schedule; Hemofiltration; Humans; Microbial Sensitivity Tests; Middle Aged | 2009 |